134 related articles for article (PubMed ID: 35317947)
1. Meta-analysis on prognostic value of KRAS mutation in resected mass-forming cholangiocarcinoma.
Procopio F; Branciforte B; Nappo G; Di Tommaso L; Lleo A; Torzilli G
Eur J Surg Oncol; 2022 Jul; 48(7):1455-1463. PubMed ID: 35317947
[TBL] [Abstract][Full Text] [Related]
2. Does KRAS mutation status impact the risk of local recurrence after R1 vascular resection for colorectal liver metastasis? An observational cohort study.
Procopio F; Viganò L; Cimino M; Donadon M; Del Fabbro D; Torzilli G
Eur J Surg Oncol; 2020 May; 46(5):818-824. PubMed ID: 31839435
[TBL] [Abstract][Full Text] [Related]
3. Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by
Ikeno Y; Seo S; Iwaisako K; Yoh T; Nakamoto Y; Fuji H; Taura K; Okajima H; Kaido T; Sakaguchi S; Uemoto S
J Transl Med; 2018 Apr; 16(1):95. PubMed ID: 29642912
[TBL] [Abstract][Full Text] [Related]
4. Association of KRAS Variant Subtypes With Survival and Recurrence in Patients With Surgically Treated Intrahepatic Cholangiocarcinoma.
Zhou SL; Xin HY; Sun RQ; Zhou ZJ; Hu ZQ; Luo CB; Wang PC; Li J; Fan J; Zhou J
JAMA Surg; 2022 Jan; 157(1):59-65. PubMed ID: 34730772
[TBL] [Abstract][Full Text] [Related]
5. [Prognosis after resection of intrahepatic cholangiocarcinoma: clinical significance of KRAS mutations].
Schneider MA; Büchler MW
Chirurg; 2022 Mar; 93(3):306-307. PubMed ID: 35175401
[No Abstract] [Full Text] [Related]
6. Is the outcome after hepatectomy for transitional hepatocholangiocarcinoma different from that of hepatocellular carcinoma and mass-forming cholangiocarcinoma? A case-matched analysis.
Gentile D; Donadon M; Di Tommaso L; Samà L; Franchi E; Costa G; Lleo A; Torzilli G
Updates Surg; 2020 Sep; 72(3):671-679. PubMed ID: 32445033
[TBL] [Abstract][Full Text] [Related]
7. KRAS mutation in intrahepatic cholangiocarcinoma: Linkage with metastasis-free survival and reduced E-cadherin expression.
Tanaka M; Kunita A; Yamagishi M; Katoh H; Ishikawa S; Yamamoto H; Abe J; Arita J; Hasegawa K; Shibata T; Ushiku T
Liver Int; 2022 Oct; 42(10):2329-2340. PubMed ID: 35833881
[TBL] [Abstract][Full Text] [Related]
8. Genetic Determinants of Outcome in Intrahepatic Cholangiocarcinoma.
Boerner T; Drill E; Pak LM; Nguyen B; Sigel CS; Doussot A; Shin P; Goldman DA; Gonen M; Allen PJ; Balachandran VP; Cercek A; Harding J; Solit DB; Schultz N; Kundra R; Walch H; D'Angelica MI; DeMatteo RP; Drebin J; Kemeny NE; Kingham TP; Simpson AL; Hechtman JF; Vakiani E; Lowery MA; Ijzermans JNM; Buettner S; Koerkamp BG; Doukas M; Chandwani R; Jarnagin WR
Hepatology; 2021 Sep; 74(3):1429-1444. PubMed ID: 33765338
[TBL] [Abstract][Full Text] [Related]
9. K-ras mutation is strongly associated with perineural invasion and represents an independent prognostic factor of intrahepatic cholangiocarcinoma after hepatectomy.
Chen TC; Jan YY; Yeh TS
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S675-81. PubMed ID: 22805857
[TBL] [Abstract][Full Text] [Related]
10. Intrahepatic cholangiocarcinoma: prognostic factors after surgical resection.
Guglielmi A; Ruzzenente A; Campagnaro T; Pachera S; Valdegamberi A; Nicoli P; Cappellani A; Malfermoni G; Iacono C
World J Surg; 2009 Jun; 33(6):1247-54. PubMed ID: 19294467
[TBL] [Abstract][Full Text] [Related]
11. Resection of Colorectal Liver Metastasis: Prognostic Impact of Tumor Burden vs KRAS Mutational Status.
Tsilimigras DI; Hyer JM; Bagante F; Guglielmi A; Ruzzenente A; Alexandrescu S; Poultsides G; Sasaki K; Aucejo F; Pawlik TM
J Am Coll Surg; 2021 Apr; 232(4):590-598. PubMed ID: 33383214
[TBL] [Abstract][Full Text] [Related]
12. Treatment and Prognosis for Patients With Intrahepatic Cholangiocarcinoma: Systematic Review and Meta-analysis.
Mavros MN; Economopoulos KP; Alexiou VG; Pawlik TM
JAMA Surg; 2014 Jun; 149(6):565-74. PubMed ID: 24718873
[TBL] [Abstract][Full Text] [Related]
13. Does high-grade dysplasia/carcinoma in situ of the biliary duct margin affect the prognosis of extrahepatic cholangiocarcinoma? A meta-analysis.
Ke Q; Wang B; Lin N; Wang L; Liu J
World J Surg Oncol; 2019 Dec; 17(1):211. PubMed ID: 31818290
[TBL] [Abstract][Full Text] [Related]
14. Mutations of p53 tumor suppressor gene, apoptosis, and proliferation in intrahepatic cholangiocellular carcinoma of the liver.
Tannapfel A; Weinans L; Geissler F; Schütz A; Katalinic A; Köckerling F; Hauss J; Wittekind C
Dig Dis Sci; 2000 Feb; 45(2):317-24. PubMed ID: 10711445
[TBL] [Abstract][Full Text] [Related]
15. Impact of Remnant Carcinoma in Situ at the Ductal Stump on Long-Term Outcomes in Patients with Distal Cholangiocarcinoma.
Yasukawa K; Shimizu A; Motoyama H; Kubota K; Notake T; Fukushima K; Ikehara T; Hayashi H; Kobayashi A; Soejima Y
World J Surg; 2021 Jan; 45(1):291-301. PubMed ID: 32989580
[TBL] [Abstract][Full Text] [Related]
16. Effect of KRAS and BRAF Mutations on Survival of Metastatic Colorectal Cancer After Liver Resection: A Systematic Review and Meta-Analysis.
Tosi F; Magni E; Amatu A; Mauri G; Bencardino K; Truini M; Veronese S; De Carlis L; Ferrari G; Nichelatti M; Sartore-Bianchi A; Siena S
Clin Colorectal Cancer; 2017 Sep; 16(3):e153-e163. PubMed ID: 28216246
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of vascular resection associated with curative intent hepatectomy for intrahepatic cholangiocarcinoma.
Conci S; Viganò L; Ercolani G; Gonzalez E; Ruzzenente A; Isa G; Salaris C; Fontana A; Bagante F; Pedrazzani C; Campagnaro T; Iacono C; De Santibanes E; Pinna DA; Torzilli G; Guglielmi A
Eur J Surg Oncol; 2020 Sep; 46(9):1727-1733. PubMed ID: 32360063
[TBL] [Abstract][Full Text] [Related]
18. Patterns of gene mutations in bile duct cancers: is it time to overcome the anatomical classification?
Bagante F; Ruzzenente A; Conci S; Rusev BC; Simbolo M; Campagnaro T; Pawlik TM; Luchini C; Iacono C; Scarpa A; Guglielmi A
HPB (Oxford); 2019 Dec; 21(12):1648-1655. PubMed ID: 31122820
[TBL] [Abstract][Full Text] [Related]
19. Correlation between KRAS gene mutations and linicopathological features of patients with intrahepatic cholangiocarcinoma.
Wang J; Xu MX; Wang LQ; Li HY; Wang ZL; Li LJ
J Biol Regul Homeost Agents; 2019; 33(5):1551-1557. PubMed ID: 31635679
[No Abstract] [Full Text] [Related]
20. Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: Does the primary disease site matter?
Amini N; Andreatos N; Margonis GA; Buettner S; Wang J; Galjart B; Wagner D; Sasaki K; Angelou A; Sun J; Kamphues C; Beer A; Morioka D; Løes IM; Antoniou E; Imai K; Pikoulis E; He J; Kaczirek K; Poultsides G; Verhoef C; Lønning PE; Endo I; Baba H; Kornprat P; NAucejo F; Kreis ME; Christopher WL; Weiss MJ; Safar B; Burkhart RA
J Hepatobiliary Pancreat Sci; 2022 Apr; 29(4):417-427. PubMed ID: 34614304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
